Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Assets (2019 - 2025)

C4 Therapeutics' Current Assets history spans 7 years, with the latest figure at $258.1 million for Q4 2025.

  • For Q4 2025, Current Assets changed 0.13% year-over-year to $258.1 million; the TTM value through Dec 2025 reached $258.1 million, changed 0.13%, while the annual FY2025 figure was $258.1 million, 0.13% changed from the prior year.
  • Current Assets reached $258.1 million in Q4 2025 per CCCC's latest filing, up from $206.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $477.6 million in Q2 2021 to a low of $206.9 million in Q3 2025.
  • Average Current Assets over 5 years is $291.4 million, with a median of $277.2 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 97.34% in 2021, then plummeted 33.34% in 2022.
  • A 5-year view of Current Assets shows it stood at $325.7 million in 2021, then decreased by 11.71% to $287.6 million in 2022, then decreased by 5.69% to $271.2 million in 2023, then dropped by 4.95% to $257.8 million in 2024, then increased by 0.13% to $258.1 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Current Assets are $258.1 million (Q4 2025), $206.9 million (Q3 2025), and $224.7 million (Q2 2025).